[{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Beximco Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beximco Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beximco Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"InCarda Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"PhysIQ","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Flecainide","moa":"Sodium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"InCarda Therapeutics \/ physIQ","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ physIQ"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Flecainide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InCarda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InCarda Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Flecainide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.

                          Brand Name : FlecIH-103

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : Flecainide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status :

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.

                          Brand Name : Inrhythm

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 24, 2022

                          Lead Product(s) : Flecainide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : PhysIQ

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.

                          Brand Name : InRhythm

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 09, 2021

                          Lead Product(s) : Flecainide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.

                          Brand Name : FlecIH

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 21, 2020

                          Lead Product(s) : Flecainide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Innoviva

                          Deal Size : Undisclosed

                          Deal Type : Series C Financing

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).

                          Brand Name : InRhythm

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 21, 2020

                          Lead Product(s) : Flecainide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Deerfield Management

                          Deal Size : $30.0 million

                          Deal Type : Series C Financing

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 21, 2020

                          Lead Product(s) : Flecainide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank